Paper Key : IRJ************035
Author: Mutadak Rutuja Sudesh
Date Published: 03 Feb 2025
Abstract
The class of drugs that competitively block the potassium binding site of gastric H+K+ ATPase, thus potentially overcoming the limitations of proton-pump inhibitors. Different studies evaluated the efficacy of vonoprazan versus proton-pump inhibitors (PPIs) for the treatment of acid-related disorders, and, therefore, P-CABs present the same indications of PPIs: gastroesophageal reflux disease, gastric and duodenal ulcer healing, management of upper gastrointestinal bleeding, nonsteroidal anti-inflammatory drug (NSAID)-associated ulcers and Helicobacter pylori eradication therapy. the role of vonoprazan for the treatment of peptic ulcer disease (PUD) and the management of gastric ulcer occurring after endoscopic submucosal dissection (ESD).In pre-clinical studies, VPZ was unaffected by changes in pH, making it 1.22 times more potent than PPI, both in-vivo and in-vitro. Vonoprazan (aka TAK-438), has been approved for clinical use in Japan to reduce intragastric pH. VPZ is a potassium-competitive acid blocker (P-CAB). This review article suggests that Vonoprazan is 400 times more efficacious than PPIs. The safety profile of Vonoprazan in Reflux Gastritis is just similar to that of PPI use. Also, VPZ is much more costeffective as compared to PPI's.
DOI Requested